FUNDAMENTALS · Fundamentals · US Healthcare

MediciNova (4875) Fundamentals 2026 — Revenue Analysis | SniperIQ

MediciNova (4875) is a US-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥10.7B, trading at ¥217.00 on the JPX. This SniperIQ fundamentals page covers MediciNova's valuation, profitability (net margin -1964.3%), revenue ($409,657 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥10.7B
Net Margin-1964.3%
Revenue (FY25)$409,657

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is MediciNova's market cap?

MediciNova (4875) has a market capitalization of approximately ¥10.7B, trading at ¥217.00 on the JPX. Market cap moves with the live share price.

What is MediciNova's P/E ratio?

MediciNova's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is MediciNova?

MediciNova runs a net profit margin of -1964.3%, a gross margin of 15.2%, and an operating margin of -2164.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does MediciNova generate?

MediciNova reported revenue of $409,657 for fiscal year 2025, with net income of -

2M and earnings per share (EPS) of -0.24. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does MediciNova pay a dividend?

MediciNova does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is MediciNova financially healthy?

MediciNova carries a debt-to-equity ratio of 0.00x and a current ratio of 9.09x, with a market beta of 0.62. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is MediciNova a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MediciNova (4875) the key facts are: market cap ¥10.7B, revenue $409,657, 52-week range 174-314. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track MediciNova's full fundamentals live

Get MediciNova's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Dian Diagnostics Group (300244) fundamentals · GENOVA (9341) fundamentals · Polaris Group (6550) fundamentals · Charles River Laboratories International (CRL) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons